Abstract
Abstract Background and Aims: Breast cancer (BC) is the leading cause of mortality among all cancers in Bangladeshi women. The prognosis of metastatic breast cancer depends on certain factors, like surgery, radiotherapy, chemotherapy, hormonal receptor content of the tumor or associated illness such as diabetes mellitus and obesity. Among the associated illness, diabetes mellitus is one of the most common metabolic disease worldwide, which is linked to an increased risk of developing breast cancer and an even higher risk of recurrence and dying from this disease. In this context, we studied diabetic and metabolic disease related growth and metabolic factors in breast cancer patients for assessing the prognosis of BC. Methods: A total of 180 mastectomy patients were purposively taken in the present study. Data were collected from retrospective information. Anthropometric and biochemical parameters were taken by standard methods. Growth and metabolic factors were determined by enzyme-linked immunosorbent assay (ELISA) method. Association of diabetes treatment modalities with breast cancer metastasis was evaluated by correlation analysis among 80 diabetic patients. Results: Serum level of insulin-like growth factor 1 (IGF1) was found to be significantly higher (p=0.001) in ER and PR negative breast cancer than their positive counterparts. Patients who had lymph node positive and Her2 borderline showed a significant reduction in serum adiponectin level (p<0.05) and this association was retained after adjusting the confounding variables. Furthermore, delayed treatment, IGF-1, ALP, sleeping hours were significant predictors for metastasis of breast cancer patients in Bangladesh. The Diabetic BC patients treated with both insulin and oral drug was found to be negatively associated with breast cancer metastasis compared to Diabetic-BC patients treated with only oral drugs (p<0.05). However, BC metastasis did not any have an association with serum fasting insulin or insulin resistance. Obesity also did not show any relation with BC prognosis. Conclusions: Serum IGF-1 and adiponectin may have an association with invasiveness and metastasis of breast cancer. Diabetes treatment with combination therapy ameliorates breast cancer metastasis.Breast cancer prognosis would be independently predict by serum levels of IGF-1 as well as IGF1 could be used as a screening biomarker when validated in a larger sample size. Citation Format: Salima Akter, Muhammad Saiedullah, Mousumi Bhowmik, Hajara Akhter, Shahina Ansary, Waheed Akhtar, Sufi Hannan Zulfiqur Rahman, Tae Gyu Choi, Sung Soo Kim. Predicting the metastatic potential in breast cancer patients in Bangladesh [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 2099.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.